JOHNSON & JOHNSON - FORM 8-K - EX-99.2 - October 13, 2020

Attached files

file filename
EX-99.1 - EX-99.1 - JOHNSON & JOHNSONa2020q3exhibit991.htm
8-K - 8-K - JOHNSON & JOHNSONjnj-20201013.htm

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)THIRD QUARTER
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $11,086  10,791  2.7 % 2.7  -
Europe 4,819  4,461 8.0  4.6  3.4
Western Hemisphere excluding U.S. 1,296  1,488  (12.9) (1.2) (11.7)
Asia-Pacific, Africa 3,881  3,989  (2.7) (3.2) 0.5
International 9,996  9,938  0.6  0.6  0.0
      
Worldwide $21,082  20,729  1.7 % 1.7  0.0
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)NINE MONTHS
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $31,324  31,323 0.0 %0.0  -
Europe 13,709  13,803  (0.7) 0.1  (0.8)
Western Hemisphere excluding U.S. 3,931  4,446  (11.6) (0.4) (11.2)
Asia-Pacific, Africa 11,145  11,740  (5.1) (4.3) (0.8)
International 28,785  29,989  (4.0) (1.7) (2.3)
      
Worldwide $60,109  61,312  (2.0)% (0.8) (1.2)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.







Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)THIRD QUARTER
 Percent Change
20202019TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,556 1,394 11.6 %11.6— 
    International1,958 2,075 (5.6)(2.7)(2.9)
3,514    3,469 1.3 3.0 (1.7)
Pharmaceutical
    U.S.6,438 6,340 1.5 1.5— 
    International4,980 4,537 9.7 8.80.9 
11,418    10,877 5.0 4.60.4 
Medical Devices
    U.S.3,092    3,057 1.2 1.2 — 
    International3,058 3,326 (8.1)(8.5)0.4 
 6,150    6,383 (3.6)(3.9)0.3 
U.S.11,086 10,791 2.7 2.7 — 
International9,996 9,938 0.6 0.6 0.0 
Worldwide$21,082 20,729 1.7 1.7 0.0 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)NINE MONTHS
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$4,853  4,369  11.1 % 11.1  -
    International 5,582  5,962  (6.4) (2.2) (4.2)
 10,435     10,331  1.0  3.4  (2.4)
Pharmaceutical
    U.S. 18,619  17,705  5.2  5.2  -
    International 14,685  13,945  5.3  7.4  (2.1)
 33,304     31,650  5.2  6.1  (0.9)
Medical Devices
    U.S. 7,852     9,249  (15.1) (15.1) -
    International 8,518  10,082  (15.5) (14.1) (1.4)
  16,370     19,331  (15.3) (14.6) (0.7)
U.S. 31,324  31,323 0.0 0.0  -
International 28,785  29,989  (4.0) (1.7) (2.3)
Worldwide$60,109  61,312  (2.0) (0.8) (1.2)
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)THIRD QUARTER
20202019Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$21,082 100.0$20,729 100.01.7 
Cost of products sold6,972 33.16,867 33.11.5 
Gross Profit14,110 66.913,862 66.91.8 
Selling, marketing and administrative expenses5,431 25.85,374 26.01.1 
Research and development expense2,840 13.52,599 12.59.3 
In-process research and development138 0.6 — —  
Interest (income) expense, net32 0.1 (41)(0.2) 
Other (income) expense, net1,200 5.7 4,214 20.3  
Restructuring68 0.369 0.4 
Earnings before provision for taxes on income4,401 20.91,647 7.9167.2 
Provision for/(Benefit from) taxes on income847 4.0(106)(0.6) 
Net earnings$3,554 16.9$1,753 8.5102.7 
Net earnings per share (Diluted)$1.33 $0.66 101.5 
Average shares outstanding (Diluted)2,669.3 2,669.9 
Effective tax rate19.2 %(6.4)%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$7,246 34.4$7,116 34.31.8 
Net earnings$5,868 27.8$5,672 27.43.5 
Net earnings per share (Diluted)$2.20 $2.12 3.8 
Effective tax rate19.0 %20.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.








Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)NINE MONTHS
20202019Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$60,109  100.0 $61,312  100.0 (2.0)
Cost of products sold 20,613  34.3  20,422  33.3 0.9
Gross Profit 39,496  65.7  40,890  66.7 (3.4)
Selling, marketing and administrative expenses 15,627  26.0  16,139  26.3 (3.2)
Research and development expense 8,127  13.5  8,123  13.3 0.0
In-process research and development 144  0.3  890  1.4  
Interest (income) expense, net 16  0.0  (43) (0.1) 
Other (income) expense, net 545  0.9  2,509  4.1  
Restructuring 187  0.3  162  0.3  
Earnings before provision for taxes on income 14,850  24.7  13,110  21.4 13.3
Provision for taxes on income 1,874  3.1  2,001  3.3 (6.3)
Net earnings$12,976  21.6 $11,109  18.1 16.8
Net earnings per share (Diluted)$4.86 $4.13 17.7
Average shares outstanding (Diluted)2,670.82,688.1
Effective tax rate12.6%15.3%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$19,827 33.0$22,597 36.9(12.3)
Net earnings$16,468 27.4$18,283 29.8(9.9)
Net earnings per share (Diluted)$6.17 $6.80 (9.3)
Effective tax rate16.9%19.1%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Third Quarter
(Dollars in Millions Except Per Share Data)20202019
Net Earnings, after tax- as reported$3,554$1,753
Pre-tax Adjustments
Intangible Asset Amortization expense1,1811,138
Litigation expense, net1,4774,000
IPR&D138-
Restructuring related130128
Acquisition and Integration related ¹(154)107
Unrealized (gains)/losses on securities3289
Medical Device Regulation 2
38-
Other37
Tax Adjustments
Tax impact on special item adjustments 3
(482)(1,159)
Tax legislation and related impacts(49)(391)
Adjusted Net Earnings, after tax$5,868$5,672
Average shares outstanding (Diluted)2,669.32,669.9
Adjusted net earnings per share (Diluted)$2.20$2.12
Operational adjusted net earnings per share (Diluted)$2.17
Notes:
1
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
3
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.






Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Nine Months Ended
(Dollars in Millions Except Per Share Data)20202019
Net Earnings, after tax- as reported$12,976$11,109
Pre-tax Adjustments
Intangible Asset Amortization expense3,4263,386
Litigation expense, net2,2104,832
IPR&D144890
Restructuring related363360
Acquisition and Integration related ¹(1,087)229
Unrealized (gains)/losses on securities(174)(217)
Medical Device Regulation 2
89-
Other67
Tax Adjustments
Tax impact on special item adjustments 3
(1,002)(1,922)
Tax legislation and related impacts(483)(391)
Adjusted Net Earnings, after tax$16,468$18,283
Average shares outstanding (Diluted)2,670.82,688.1
Adjusted net earnings per share (Diluted)$6.17$6.80
Operational adjusted net earnings per share (Diluted)$6.18
Notes:
1
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
3
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
THIRD QUARTER 2020 ACTUAL vs. 2019 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 1.3 %5.0 %(3.6)%1.7 %
 U.S. 11.6 %1.5 %1.2 %2.7 %
 International (5.6)%9.7 %(8.1)%0.6 %
 WW Currency (1.7)0.40.30.0
 U.S. ————
 International (2.9)0.90.40.0
 WW Operational 3.0 %4.6 %(3.9)%1.7 %
 U.S. 11.6 %1.5 %1.2 %2.7 %
 International (2.7)%8.8 %(8.5)%0.6 %
General Surgery
Advanced Sterilization Products0.50.2
 U.S. 0.00.0
 International 0.90.4
Baby Care
Baby Center0.10.0
 U.S. 0.40.1
 International 0.00.0
All Other Acquisitions and Divestitures0.00.10.00.1
 U.S. 0.00.00.10.0
 International (0.1)0.30.00.1
WW Adjusted Operational3.1 %4.7 %(3.3)%2.0 %
 U.S. 12.0 %1.5 %1.3 %2.8 %
 International (2.8)%9.2 %(7.6)%1.1 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.








Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
NINE MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments
Consumer HealthPharmaceuticalMedical DevicesTotal
WW As Reported1.0 %5.2 %(15.3)%(2.0)%
U.S.11.1 %5.2 %(15.1)%0.0 %
International(6.4)%5.3 %(15.5)%(4.0)%
WW Currency(2.4)(0.9)(0.7)(1.2)
U.S.————
International(4.2)(2.1)(1.4)(2.3)
WW Operational3.4 %6.1 %(14.6)%(0.8)%
U.S.11.1 %5.2 %(15.1)%0.0 %
International(2.2)%7.4 %(14.1)%(1.7)%
Skin Health / Beauty
Dr. Ci Labo - Japan(0.1)0.0
U.S.0.00.0
International(0.2)0.0
General Surgery
Advanced Sterilization Products0.90.3
U.S.0.80.3
International0.90.4
Baby Care
Baby Center0.20.0
U.S.0.60.1
International0.00.0
All Other Acquisitions and Divestitures(0.1)0.20.00.1
U.S.0.00.00.00.0
International(0.1)0.30.00.1
WW Adjusted Operational3.4 %6.3 %(13.7)%(0.4)%
U.S.11.7 %5.2 %(14.3)%0.4 %
International(2.6)%7.7 %(13.1)%(1.3)%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$60147726.0 %26.0 %— %
Intl541621(12.9)(12.9)0.0 
WW1,1421,0984.0 4.0 0.0 
SKIN HEALTH / BEAUTY (4)
US5725592.4 2.4 — 
Intl577592(2.7)(0.5)(2.2)
WW1,149 1,151(0.2)0.9 (1.1)
ORAL CARE
US1641565.5 5.5 — 
Intl24822310.7 14.4 (3.7)
WW412 379 8.5 10.8 (2.3)
BABY CARE
US9191(1.0)(1.0)— 
Intl302326(7.2)(0.6)(6.6)
WW393 417 (5.9)(0.7)(5.2)
WOMEN'S HEALTH
US33(6.9)(6.9)— 
Intl227252(9.6)(4.0)(5.6)
WW230255(9.6)(4.1)(5.5)
WOUND CARE / OTHER
US12510915.2 15.2 — 
Intl64597.4 10.3 (2.9)
WW18916812.5 13.5 (1.0)
TOTAL CONSUMER HEALTH
US1,556 1,394 11.6 11.6 — 
Intl1,958 2,075 (5.6)(2.7)(2.9)
WW$3,514 3,469 1.3 %3.0 %(1.7)%
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5)
IMMUNOLOGY
US$2,5582,582(0.9)%(0.9)%— %
Intl1,2301,1299.0 8.4 0.6 
WW3,7893,7112.1 1.9 0.2 
     REMICADE
     US634749(15.4)(15.4)— 
     US Exports (6)
7888(11.3)(11.3)— 
     Intl209299(30.1)(28.0)(2.1)
     WW9211,136(18.9)(18.4)(0.5)
     SIMPONI / SIMPONI ARIA
     US312313(0.4)(0.4)— 
     Intl2802732.4 2.2 0.2 
     WW5925860.9 0.8 0.1 
     STELARA
     US1,3131,2128.4 8.4 — 
     Intl63448730.3 28.1 2.2 
     WW1,9471,69814.7 14.0 0.7 
     TREMFYA
     US222 221 0.4 0.4 — 
     Intl105 69 54.4 50.4 4.0 
     WW327 290 13.1 12.2 0.9 
     OTHER IMMUNOLOGY
     US— — — — — 
     Intl3235.6 44.6 (9.0)
     WW3235.6 44.6 (9.0)
INFECTIOUS DISEASES
US413418(1.1)(1.1)— 
Intl4514217.0 6.3 0.7 
WW8648393.0 2.6 0.4 
     EDURANT / rilpivirine
     US11 12 (12.0)(12.0)— 
     Intl226 206 9.3 5.0 4.3 
     WW236 218 8.1 4.1 4.0 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US3793731.5 1.5 — 
     Intl1471359.1 12.1 (3.0)
     WW5265083.5 4.3 (0.8)
     OTHER INFECTIOUS DISEASES
     US2433(26.6)(26.6)— 
     Intl7880(2.3)(0.4)(1.9)
     WW102113(9.4)(8.1)(1.3)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
NEUROSCIENCE
US$759785(3.5)%(3.5)%— %
Intl8468104.5 4.1 0.4 
WW1,6051,5950.6 0.4 0.2 
     CONCERTA / methylphenidate
     US4384(49.2)(49.2)— 
     Intl107109(2.0)(1.7)(0.3)
     WW149193(22.6)(22.5)(0.1)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US5855545.6 5.6 — 
     Intl341297 14.9 12.6 2.3 
     WW9268518.8 8.0 0.8 
     RISPERDAL CONSTA
     US7079(11.0)(11.0)— 
     Intl8189(7.8)(8.9)1.1 
     WW152167(9.3)(9.9)0.6 
     OTHER NEUROSCIENCE
     US6068(11.3)(11.3)— 
     Intl3173160.3 1.7 (1.4)
     WW377384(1.8)(0.6)(1.2)
ONCOLOGY
US1,2671,1718.2 8.2 — 
Intl1,862 1,590 17.1 15.5 1.6 
WW3,1292,76113.3 12.4 0.9 
     DARZALEX
     US585 402 46.0 46.0 — 
     Intl514 363 41.5 40.5 1.0 
     WW1,099 765 43.8 43.4 0.4 
     ERLEADA
     US152 74 **— 
     Intl55 12 ***
     WW206 86 ***
     IMBRUVICA
     US450 447 0.7 0.7 — 
     Intl581 475 22.5 21.2 1.3 
     WW1,031 921 11.9 11.2 0.7 
     VELCADE
     US— — — — — 
     Intl105149(30.1)(30.8)0.7 
     WW105149(30.1)(30.8)0.7 
     ZYTIGA / abiraterone acetate
     US58233 (75.2)(75.2)— 
     Intl5325084.8 2.2 2.6 
     WW590741(20.4)(22.1)1.7 
     OTHER ONCOLOGY
     US21 17 35.3 35.3 — 
     Intl7683(8.8)(10.1)1.3 
     WW98100(1.7)(2.8)1.1 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
PULMONARY HYPERTENSION
US$510 427 19.4 %19.4 %— %
Intl239 227 5.2 3.7 1.5 
WW749 654 14.5 13.9 0.6 
     OPSUMIT
     US244 206 18.1 18.1 — 
     Intl148 140 5.5 3.9 1.6 
     WW392 347 13.0 12.3 0.7 
     UPTRAVI
     US226 185 22.4 22.4 — 
     Intl34 25 32.3 28.9 3.4 
     WW260 210 23.6 23.2 0.4 
     OTHER PULMONARY HYPERTENSION
     US40 36 11.5 11.5 — 
     Intl57 61 (6.7)(7.4)0.7 
     WW97 96 0.1 (0.3)0.4 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$931955(2.6)%(2.6)%— %
Intl351360(2.7)(2.4)(0.3)
WW1,2811,316(2.6)(2.5)(0.1)
     XARELTO
     US630 613 2.9 2.9 — 
     Intl— — — — — 
     WW630 613 2.9 2.9 — 
     INVOKANA / INVOKAMET
     US156 125 24.7 24.7 — 
     Intl68 55 24.7 25.2 (0.5)
     WW224 179 24.7 24.9 (0.2)
     PROCRIT / EPREX
     US69 126 (45.4)(45.4)— 
     Intl63 72 (12.2)(13.0)0.8 
     WW132 198 (33.3)(33.6)0.3 
     OTHER
     US75 91 (17.9)(17.9)— 
     Intl219 234 (6.2)(5.5)(0.7)
     WW294 325 (9.5)(9.0)(0.5)
TOTAL PHARMACEUTICAL
US6,4386,3401.5 1.5 — 
Intl4,9804,5379.7 8.8 0.9 
WW$11,41810,8775.0 %4.6 %0.4 %
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5)
INTERVENTIONAL SOLUTIONS
US$399 357 11.8 %11.8 %— %
Intl437 38214.0 12.9 1.1 
WW836 74112.9 12.4 0.5 
ORTHOPAEDICS
US1,308 1,301 0.6 0.6 — 
Intl774 837 (7.5)(9.0)1.5 
WW2,083 2,138 (2.6)(3.1)0.5 
     HIPS
     US221 204 8.7 8.7 — 
     Intl124 133 (7.2)(8.4)1.2 
     WW345 336 2.4 1.9 0.5 
     KNEES
     US205 209 (1.9)(1.9)— 
     Intl102 136 (24.8)(26.4)1.6 
     WW308 344 (10.9)(11.6)0.7 
     TRAUMA
     US433 415 4.2 4.2 — 
     Intl253 262 (3.4)(4.7)1.3 
     WW685 677 1.3 0.7 0.6 
     SPINE, SPORTS & OTHER (7)
     US449 472 (4.9)(4.9)— 
     Intl295 306 (3.4)(5.0)1.6 
     WW745 778 (4.3)(5.0)0.7 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued)
SURGERY
US$913 940 (3.0)%(3.0)%— %
Intl1,239 1,371 (9.6)(9.5)(0.1)
WW2,152 2,311 (6.9)(6.9)0.0 
     ADVANCED
     US421 409 3.0 3.0 — 
     Intl579 602 (3.9)(4.1)0.2 
     WW1,000 1,010 (1.1)(1.2)0.1 
     GENERAL
     US492 531 (7.6)(7.6)— 
     Intl660 769 (14.1)(13.8)(0.3)
     WW1,152 1,301 (11.4)(11.3)(0.1)
VISION
US473 459 3.1 3.1 — 
Intl608 734 (17.2)(17.4)0.2 
WW1,081 1,193 (9.4)(9.5)0.1 
     CONTACT LENSES / OTHER
     US375 339 10.9 10.9 — 
     Intl455 555 (18.1)(18.2)0.1 
     WW830 893 (7.1)(7.2)0.1 
     SURGICAL
     US98 120 (18.9)(18.9)— 
     Intl153 180 (14.6)(14.8)0.2 
     WW251 299 (16.3)(16.4)0.1 
TOTAL MEDICAL DEVICES
US3,092 3,057 1.2 1.2 — 
Intl3,058 3,326 (8.1)(8.5)0.4 
WW$6,150 6,383 (3.6)%(3.9)%0.3 %
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$1,917 1,468 30.6 %30.6 %— %
Intl1,722 1,781 (3.3)(0.6)(2.7)
WW3,639 3,249 12.0 13.5 (1.5)
SKIN HEALTH / BEAUTY (4)
US1,767 1,810 (2.4)(2.4)—
Intl1,506 1,633 (7.8)(4.9)(2.9)
WW3,273 3,443 (5.0)(3.6)(1.4)
ORAL CARE
US510 462 10.4 10.4 —
Intl694 673 3.0 7.9 (4.9)
WW1,204 1,135 6.0 8.9 (2.9)
BABY CARE
US279 277 0.5 0.5 —
Intl831 977 (14.9)(8.6)(6.3)
WW1,110 1,254 (11.5)(6.6)(4.9)
WOMEN'S HEALTH
US10 9 7.3 7.3 —
Intl654 724 (9.6)(2.8)(6.8)
WW664 733 (9.4)(2.7)(6.7)
WOUND CARE / OTHER
US370 343 8.0 8.0 —
Intl175 173 1.3 5.4 (4.1)
WW545 516 5.8 7.2 (1.4)
TOTAL CONSUMER HEALTH
US4,853 4,369 11.1 11.1 —
Intl5,582 5,962 (6.4)(2.2)(4.2)
WW$10,435 10,331 1.0 %3.4 %(2.4)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5)
IMMUNOLOGY
US$7,330 7,124 2.9 %2.9 %— %
Intl3,619 3,304 9.5 11.9 (2.4)
WW10,950 10,428 5.0 5.7 (0.7)
     REMICADE
     US1,852 2,324 (20.3)(20.3)—
     US Exports (6)
321 226 42.1 42.1 —
     Intl673 795 (15.3)(11.6)(3.7)
     WW2,846 3,345 (14.9)(14.0)(0.9)
     SIMPONI / SIMPONI ARIA
     US840 857 (2.0)(2.0)—
     Intl827 816 1.3 3.9 (2.6)
     WW1,667 1,673 (0.4)0.9 (1.3)
     STELARA
     US3,668 3,152 16.4 16.4 —
     Intl1,795 1,509 19.0 20.6 (1.6)
     WW5,463 4,661 17.2 17.7 (0.5)
     TREMFYA
     US650 565 15.0 15.0 —
     Intl316 177 78.7 79.1 (0.4)
     WW965 742 30.2 30.3 (0.1)
     OTHER IMMUNOLOGY
     US— — ———
     Intl9 8 12.4 19.1 (6.7)
     WW9 8 12.4 19.1 (6.7)
INFECTIOUS DISEASES
US1,265 1,162 8.9 8.9 —
Intl1,397 1,385 0.9 3.8 (2.9)
WW2,662 2,547 4.5 6.1 (1.6)
     EDURANT / rilpivirine
     US33 36 (8.6)(8.6)—
     Intl684 603 13.3 13.8 (0.5)
     WW716 639 12.1 12.6 (0.5)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US1,154 1,032 11.8 11.8 —
     Intl461 534 (13.7)(8.8)(4.9)
     WW1,615 1,566 3.1 4.8 (1.7)
     OTHER INFECTIOUS DISEASES
     US79 94 (16.6)(16.6)—
     Intl252 248 1.8 6.3 (4.5)
     WW331 342 (3.2)0.0 (3.2)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
NEUROSCIENCE
US$2,285 2,172 5.2 %5.2 %— %
Intl2,565 2,590 (1.0)0.9 (1.9)
WW4,850 4,762 1.8 2.9 (1.1)
     CONCERTA / methylphenidate
     US150 196 (23.6)(23.6)—
     Intl319 348 (8.2)(6.4)(1.8)
     WW469 544 (13.8)(12.6)(1.2)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US1,704 1,543 10.5 10.5 —
     Intl983 916 7.3 8.6 (1.3)
     WW2,688 2,459 9.3 9.8 (0.5)
     RISPERDAL CONSTA
     US220 237 (6.9)(6.9)—
     Intl254 292 (12.7)(11.0)(1.7)
     WW475 528 (10.1)(9.2)(0.9)
     OTHER NEUROSCIENCE
     US210 196 7.1 7.1 —
     Intl1,008 1,035 (2.6)(0.1)(2.5)
     WW1,218 1,231 (1.1)1.1 (2.2)
ONCOLOGY
US3,623 3,146 15.2 15.2 —
Intl5,310 4,830 9.9 11.8 (1.9)
WW8,933 7,976 12.0 13.1 (1.1)
     DARZALEX
     US1,540 1,123 37.2 37.2 —
     Intl1,397 1,045 33.7 36.7 (3.0)
     WW2,937 2,168 35.5 37.0 (1.5)
     ERLEADA
     US407 194 **—
     Intl112 22 ***
     WW519 216 ***
     IMBRUVICA
     US1,329 1,163 14.2 14.2 —
     Intl1,682 1,373 22.5 25.2 (2.7)
     WW3,011 2,536 18.7 20.2 (1.5)
     VELCADE
     US— — ———
     Intl311 636 (51.2)(50.7)(0.5)
     WW311 636 (51.2)(50.7)(0.5)
     ZYTIGA / abiraterone acetate
     US284 616 (53.9)(53.9)—
     Intl1,564 1,502 4.1 4.8 (0.7)
     WW1,848 2,118 (12.7)(12.3)(0.4)
     OTHER ONCOLOGY
     US63 51 25.8 25.8 —
     Intl244 252 (3.1)(1.1)(2.0)
     WW308 303 1.7 3.3 (1.6)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
PULMONARY HYPERTENSION
US$1,541 1,296 18.9 %18.9 %— %
Intl742 704 5.3 6.5 (1.2)
WW2,283 2,000 14.1 14.6 (0.5)
     OPSUMIT
     US729 581 25.3 25.3 —
     Intl458 419 9.3 10.7 (1.4)
     WW1,187 1,001 18.6 19.2 (0.6)
     UPTRAVI
     US692 536 29.1 29.1 —
     Intl100 75 33.1 34.6 (1.5)
     WW792 611 29.6 29.8 (0.2)
     OTHER PULMONARY HYPERTENSION
     US121 179 (32.3)(32.3)—
     Intl183 210 (12.7)(11.9)(0.8)
     WW304 388 (21.7)(21.3)(0.4)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$2,574 2,804 (8.2)%(8.2)%— %
Intl1,052 1,131 (7.1)(4.6)(2.5)
WW3,625 3,936 (7.9)(7.2)(0.7)
     XARELTO
  
     US1,716 1,704 0.7 0.7 —
     Intl— — ———
     WW1,716 1,704 0.7 0.7 —
     INVOKANA / INVOKAMET
  
     US405 411 (1.6)(1.6)—
     Intl173 147 18.0 20.7 (2.7)
     WW578 558 3.6 4.3 (0.7)
     PROCRIT / EPREX
  
     US215 387 (44.5)(44.5)—
     Intl208 220 (5.5)(4.3)(1.2)
     WW423 607 (30.4)(29.9)(0.5)
     OTHER
  
     US238 302 (21.4)(21.4)—
     Intl670 765 (12.3)(9.5)(2.8)
     WW908 1,067 (14.9)(12.9)(2.0)
TOTAL PHARMACEUTICAL
US18,619 17,705 5.2 5.2 —
Intl14,685 13,945 5.3 7.4 (2.1)
WW$33,304 31,650 5.2 %6.1 %(0.9)%
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5)
INTERVENTIONAL SOLUTIONS
US$1,019 1,066 (4.4)%(4.4)%— %
Intl1,134 1,156 (2.0)(1.0)(1.0)
WW2,153 2,223 (3.1)(2.7)(0.4)
ORTHOPAEDICS
US3,427 3,950 (13.2)(13.2)—
Intl2,145 2,616 (18.0)(16.9)(1.1)
WW5,572 6,566 (15.1)(14.7)(0.4)
     HIPS
     US564 633 (10.9)(10.9)—
     Intl344 428 (19.8)(18.3)(1.5)
     WW908 1,061 (14.5)(13.9)(0.6)
     KNEES
     US527 650 (19.0)(19.0)—
     Intl298 435 (31.5)(30.7)(0.8)
     WW825 1,085 (24.0)(23.7)(0.3)
     TRAUMA
     US1,194 1,239 (3.6)(3.6)—
     Intl698 795 (12.2)(10.9)(1.3)
     WW1,892 2,034 (7.0)(6.5)(0.5)
     SPINE, SPORTS & OTHER (7)
     US1,142 1,427 (20.0)(20.0)—
     Intl805 957 (15.8)(14.9)(0.9)
     WW1,947 2,384 (18.3)(18.0)(0.3)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued)
SURGERY
US$2,247 2,867 (21.7)%(21.7)%— %
Intl3,556 4,192 (15.2)(13.1)(2.1)
WW5,803 7,059 (17.8)(16.6)(1.2)
     ADVANCED
     US1,079 1,209 (10.7)(10.7)—
     Intl1,644 1,811 (9.2)(7.3)(1.9)
     WW2,723 3,019 (9.8)(8.7)(1.1)
     GENERAL
     US1,168 1,658 (29.6)(29.6)—
     Intl1,912 2,381 (19.7)(17.5)(2.2)
     WW3,080 4,040 (23.8)(22.5)(1.3)
VISION
US1,160 1,366 (15.1)(15.1)—
Intl1,683 2,117 (20.5)(19.6)(0.9)
WW2,843 3,483 (18.4)(17.8)(0.6)
     CONTACT LENSES / OTHER
     US924 993 (6.9)(6.9)—
     Intl1,274 1,566 (18.7)(17.8)(0.9)
     WW2,198 2,559 (14.1)(13.6)(0.5)
     SURGICAL
     US236 373 (36.8)(36.8)—
     Intl409 551 (25.7)(24.8)(0.9)
     WW645 923 (30.2)(29.6)(0.6)
TOTAL MEDICAL DEVICES
US7,852 9,249 (15.1)(15.1)—
Intl8,518 10,082 (15.5)(14.1)(1.4)
WW$16,370 19,331 (15.3)%(14.6)%(0.7)%
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
(6) Reported as U.S. sales
(7) Previously referred to as Spine & Other



Stock widget

Investing forum

JOHNSON & JOHNSON Reports